Antifungal effect of voriconazole on intracellular Candida glabrata, Candida krusei and Candida parapsilosis in human monocyte-derived macrophages

References

1. Anaissie E. J., Rex J. H., Uzun O., Vartivarian S. 1998; Predictors of adverse outcome in cancer patients with candidemia. Am J Med 104:238–245 [CrossRef]
   [Google Scholar]
2. Baltch A. L., Smith R. P., Franke M. A., Ritz W. J., Michelsen P. B., Bopp L. H. 2001; Effects of cytokines and fluconazole on the activity of human monocytes against Candida albicans . Antimicrob Agents Chemother 45:96–104 [CrossRef]
   [Google Scholar]
3. Baltch A. L., Smith R. P., Ritz W. J., Bopp L. H., Michelsen P. B. 2005; Intracellular activity of voriconazole, fluconazole, and itraconazole against Candida albicans in human monocytes with and without activation by GM-CSF and TNF- α . J Appl Res 5:543–552
   [Google Scholar]
4. Bodey G. P., Mardani M., Hanna H. A., Boktour M., Abbas J., Girgawy E., Hachem R. Y., Kontoyiannis D. P., Raad I. I. 2002; The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 112:380–385 [CrossRef]
   [Google Scholar]
5. Draper N., Smith H. 1981a; Applied Regression Analysis. 2nd edn . p 512 New York: Wiley;
6. Draper N., Smith H. 1981b; Applied Regression Analysis . , 2nd edn. pp  85–96 New York: Wiley;
7. Ghannoum M. A., Fu Y., Ibrahim A. S., Mortara L. A., Shafiq M. C., Edward J. E. Jr, Criddle R. S. 1995; In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans . Antimicrob Agents Chemother 39:2459–2465 [CrossRef]
   [Google Scholar]
8. Girmenia C., Venditti M., Martino P. 2003; Fluconazole in combination with flucytosine in the treatment of fluconazole-resistant Candida infections. Diagn Microbiol Infect Dis 46:227–231 [CrossRef]
   [Google Scholar]
9. Loeffler J., Stevens D. A. 2003; Antifungal drug resistance. Clin Infect Dis 36:supplement 1S31–S41 [CrossRef]
   [Google Scholar]
10. Maródi L., Korchak H. M., Johnston R. B. Jr 1991a; Mechanisms of host defense against Candida species. 1. Phagocytosis by monocytes and monocyte-derived macrophages. J Immunol 146:2783–2789
    [Google Scholar]
11. Maródi L., Forehand J. R., Johnston R. B. Jr 1991b; Mechanisms of host defense against Candida species. 2. Biochemical basis for the killing of Candida by mononuclear phagocytes. J Immunol 146:2790–2794
    [Google Scholar]
12. McNeil M. M., Nash S. L., Hajjeh R. A., Phelan M. A., Conn L. A., Plikaytis B. D., Warnock D. W. 2001; Trends in mortality due to invasive mycotic disease in the United States, 1980–1997. Clin Infect Dis 33:641–647 [CrossRef]
    [Google Scholar]
13. Mukhergee P. K., Sheehan D. J., Hitchcock C. A., Ghannoum M. A. 2005; Combination treatment of invasive fungal infections. Clin Microbiol Rev 18:163–194 [CrossRef]
    [Google Scholar]
14. National Committee for Clinical Laboratory Standards 2002; Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts . Approved standard: NCCLS document M27-A2. Wayne, PA: National Committee for Clinical Laboratory Standards;
15. Ostrofsky-Zeichner L., Rex R. H., Pappas P. G. & 9 other authors; 2003; Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 47:3149–3154 [CrossRef]
    [Google Scholar]
16. Pasqual A., Garcia I., Conejo C., Perea E. P. 1993; Uptake and intracellular activity of fluconazole in human polymorphonuclear leukocytes. Antimicrob Agents Chemother 37:187–190 [CrossRef]
    [Google Scholar]
17. Pfaller M. A., Diekema D. J., Jones R. N., Messer S. A., Hollis R. J. the Sentry Participants Group 2002; Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: sentry Antimicrobial Surveillance Program, 1997–2000. J Clin Microbiol 40:852–856 [CrossRef]
    [Google Scholar]
18. Sanati H., Belanger P., Fratti R., Ghannoum M. 1997; A new triazole, voriconazole (UK 109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei . Antimicrob Agents Chemother 41:2492–2496
    [Google Scholar]
19. Sheehan D. J., Hitchcock C. A., Sibley C. M. 1999; Current and emerging azole antifungal agents. Clin Microbiol Rev 12:40–79
    [Google Scholar]
20. Stuart A., Ord J. K. 1991a Kendall's Advanced Theory of Statistics vol 2 pp  1101–1153 New York: Oxford University Press;
    [Google Scholar]
21. Stuart A., Ord J. K. 1991b Kendall's Advanced Theory of Statistics vol. 2 p. 1149section 29–58 New York: Oxford University Press;
    [Google Scholar]
22. Vora S., Purimetla N., Brummer E. 1998; Activity of voriconazole, a new triazole, combined with neutrophils and monocytes against Candida albicans : effect of G-CSF and GM-CSF. Antimicrob Agents Chemother 42:907–910
    [Google Scholar]